Efficacy and safety of endovascular arteriovenous fistula creation with comparison to surgically created fistulas: a systematic review and meta-analysis protocol v2

2021 ◽  
Author(s):  
Yoshinosuke Shimamura ◽  
Hajime Yamazaki ◽  
Takamasa Miyauchi ◽  
Hiroshi Ueta ◽  
Yasutaka Kuniyoshi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Arteriovenous Fistula ◽  
Clinical Efficacy ◽  
Meta Analysis ◽  
Systemic Review ◽  
Efficacy And Safety ◽  
Analysis Protocol

This systemic review and meta-analysis aimed to evaluated existing evidence on the clinical efficacy and safety of endovascular arteriovenous fistula creation by directly comparing it with surgical arteriovenous fistula creation among patients with chronic kidney disease requiring hemodialysis.

Abstract 96: Efficacy and Safety of Oral Anticoagulants in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Stroke ◽  
2019 ◽  
Vol 50 (Suppl_1) ◽  
Author(s):  
Konark Malhotra ◽  
Muhammad F Ishfaq ◽  
Nitin Goyal ◽  
John Parissis ◽  
Anne Alexandrov ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Meta Analysis ◽  
Oral Anticoagulants ◽  
Efficacy And Safety

scholarly journals Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Qiyan Zheng ◽  
Yahui Wang ◽  
Huisheng Yang ◽  
Luying Sun ◽  
Xinwen Fu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Binding Capacity ◽  
Meta Analysis ◽  
Transferrin Saturation ◽  
Placebo Treatment ◽  
Efficacy And Safety ◽  
Serious Adverse Events ◽  
Significant Difference

Objective: Daprodustat is a novel oral agent in treating anemia of chronic kidney disease (CKD), and several clinical trials have been conducted to compare daprodustat with recombinant human erythropoietin (rhEPO) or placebo. Our systematic review aimed to investigate the efficacy and safety of daprodustat for anemia treatment in both dialysis-dependent (DD) and non-dialysis-dependent (NDD) patients.Methods: Six databases were searched for randomized controlled trials (RCTs) reporting daprodustat vs. rhEPO or placebo for anemia patients in CKD. The outcome indicators were focused on hemoglobin (Hb), ferritin, transferrin saturation (TSAT), total iron-binding capacity (TIBC), vascular endothelial growth factor (VEGF), and serious adverse events (SAEs).Results: Eight eligible studies with 1,516 participants were included. For both NDD and DD patients, changes in Hb levels from baseline were significantly higher in daprodustat group than that in the placebo (mean difference (MD) = 1.73, [95% confidence interval (CI), 0.34 to 3.12], p = 0.01; MD = 1.88, [95% CI, 0.68 to 3.09], p = 0.002; respectively), and there was no significant difference between daprodustat and rhEPO group (MD = 0.05, [95% CI, −0.49 to 0.59], p = 0.86; MD = 0.12, [95% CI, −0.28 to 0.52], p = 0.55; respectively). The indexes of iron metabolism were improved significantly in the daprodustat group compared to placebo- or rhEPO-treated patients, while there was no similar change in terms of TSAT for DD patients. Furthermore, no trend of increasing plasma VEGF was observed in daprodustat-treated subjects. As for safety, there was no significant difference in the incidence of SAEs between daprodustat and placebo treatment, while the incidence of SAEs in the daprodustat group was significantly lower than that in the rhEPO group.Conclusion: Daprodustat was efficacious and well tolerated for anemia in both NDD and DD patients in the short term based on current RCTs. And daprodustat may become an effective alternative for treatment of anemia with CKD. Since the application of daprodustat is still under exploration, future researches should consider the limitations of our study to evaluate the value of daprodustat.

Sign in / Sign up

Export Citation Format

Share Document